You are here: Home » PTI Stories » National » News
Business Standard

Glenmark Pharma gets USFDA nod for overactive bladder treatment drug

Press Trust of India  |  New Delhi 

Pharmaceuticals has received final approval from the US health regulator for Succinate tablets, used for treatment of

The approved product is a generic version of tablets of US, Inc.

Pharmaceuticals Inc., USA, has been granted final approval by the Food and Drug Administration (USFDA) for Succinate tablets in the strengths of 5 mg and 10 mg," the company said in a BSE filing.

Quoting IQVIA sales data for the 12 month period ending March 2019, Pharma said the tablets, 5 mg and 10 mg market achieved annual sales of approximately USD 942.7 million.

The company's current portfolio consists of 154 products authorised for distribution at the US marketplace and 58 abbreviated new drug applications (ANDAs) pending approval with the

Shares of were trading 0.39 per cent higher at Rs 577.91 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 21 2019. 09:45 IST